<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Members of the tropomyosin receptor kinase (Trk) family have a high affinity for neurotrophins and regulate neuronal survival </plain></SENT>
<SENT sid="1" pm="."><plain>The role of Trks in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is still controversial </plain></SENT>
<SENT sid="2" pm="."><plain>The expression and role of TrkB and TrkC were examined in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Immunohistochemical analysis of TrkB and TrkC was performed in 133 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Using human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines, expression of vascular endothelial growth factor (VEGF) and transforming growth factor β, cell growth, invasion, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were examined by knockdown methods </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemistry showed positive results of TrkB and TrkC (23.3% and 12.8%, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>TrkB expression was associated with local progression (P = .0284), clinical stage (P = .0026), nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = .0068), and peritoneal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P = .0026) </plain></SENT>
<SENT sid="7" pm="."><plain>TrkC expression was only related to <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (P = .0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Coexpression of TrkB or TrkC and their ligands was found in 80.6% and 82.4% of cases, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In vitro analysis using human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells showed that TrkB positively regulated gene expression of VEGF-A (P &lt; .05) and VEGF-C (P &lt; .05), whereas TrkC suppressed transforming growth factor β expression (P &lt; .05) </plain></SENT>
<SENT sid="10" pm="."><plain>TrkB and TrkC induced cell growth (P &lt; .05) and invasion (P &lt; .05), respectively </plain></SENT>
<SENT sid="11" pm="."><plain>Both TrkB and TrkC showed antiapoptotic effect (P &lt; .05) </plain></SENT>
<SENT sid="12" pm="."><plain>These results suggest that TrkB and TrkC have a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> progressive function and may be a useful diagnostic and therapeutic target in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>